Nonsteroidal anti-inflammatory drugs: Prostaglandins, indications, and side effects

International Journal of Interferon, Cytokine and Mediator Research

Volumn 3, Issue 1, 2011, Pages 19-27

  Pountos, Ippokratis ^a   Georgouli, Theodora ^a   Bird, Howard ^b   Giannoudis, Peter V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Cox; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLURBIPROFEN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE; LEUKOTRIENE B4; MISOPROSTOL; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; PARACETAMOL; PEPTIDOLEUKOTRIENE; PLACEBO; PROSTAGLANDIN; PROTON PUMP INHIBITOR; ROFECOXIB;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADENOMA; ADENOMATOUS POLYP; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; ASTHMA; ASYMPTOMATIC DISEASE; BACKACHE; BILIARY COLIC; BILIARY TRACT TUMOR; BLOOD CLOTTING DISORDER; BRAIN TUMOR; BREAST TUMOR; CANCER INHIBITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CATARACT; CHRONIC PAIN; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; ENZYME INHIBITION; FETUS DISEASE; FEVER; FRACTURE HEALING; FRACTURE NONUNION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; GOUT; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATORY DISEASE; INTERSTITIAL NEPHRITIS; ISCHIALGIA; JOINT STIFFNESS; JOINT SWELLING; KIDNEY COLIC; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIVER INJURY; LOW DRUG DOSE; LUNG TUMOR; MEMBRANOUS GLOMERULONEPHRITIS; MIGRAINE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUSCLE STRAIN; MUSCULOSKELETAL INJURY; MUSCULOSKELETAL PAIN; NAUSEA; NEPHRITIS; NEUROMODULATION; NONHUMAN; OSTEOARTHRITIS; OSTEOPENIA; PAIN; PATHOPHYSIOLOGY; PEPTIC ULCER BLEEDING; POSTOPERATIVE PAIN; PREGNANCY COMPLICATION; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; PROSTHESIS LOOSENING; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; REITER SYNDROME; RESPIRATION DEPRESSION; REVIEW; REYE SYNDROME; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SEDATION; SIDE EFFECT; SPRAIN; STOMACH EROSION; STOMACH PROTECTION; STOMACH TUMOR; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT DURATION; VASCULAR DISEASE; VIRUS INFECTION;

EID: 79551512443     PISSN: None     EISSN: 1179139X     Source Type: Book Series    
DOI: 10.2147/IJICMR.S10200     Document Type: Review

References (89)

1. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27.
2. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2000;2(5):379-385.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232-235.
4. Talley NJ, Evans JM, Fleming KC, Harmsen WS, Zinsmeister AR, Melton LJ 3rd. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995;40(6):1345-1350.
5. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594-606.
6. Goldblatt WM. A depressor substance in seminal fluid. J Soc Chem Ind. 1933;52:1056-1057.
7. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96(1): 272-277.
8. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18(7):790-804.
9. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res. 2001;44(6):437-450.
10. Heller A, Koch T, Schmeck J, van Ackern K. Lipid mediators in inflammatory disorders. Drugs. 1998;55(4):487-496.
11. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
12. Vonkeman HE, van de Laar MA. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum. 2010;39(4):294-312.
13. Garavito RM, DeWitt DL. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta. 1999;1441(2-3):278-287.
14. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S-24S.
15. Trautman MS, Edwin SS, Collmer D, Dudley DJ, Simmons D, Mitchell MD. Prostaglandin H synthase-2 in human gestational tissues: regulation in amnion. Placenta. 1996;17(4):239-245.
16. Vane JR, Botting RM. Mechanism of action of nonsteroidal antiinflammatory drugs. Am J Med. 1998;104(3A):2S-8S.
17. van Ryn J, Pairet M. Clinical experience with cyclooxygenase-2 inhibitors. Inflamm Res. 1999;48(5):247-254.
18. Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci. 2009;30(4):174-181.
19. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LB. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum. 2000;43(1):4-13.
20. Teeling JL, Cunningham C, Newman TA, Perry VH. The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: implications for a role of COX-1. Brain Behav Immun. 2010; 24(3):409-419.
21. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005;72(2):85-87.
22. Berenbaum F. COX-3: fact or fancy? Joint Bone Spine. 2004;71(6): 451-453.
23. Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001;3(5):50-60.
24. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563-7568.
25. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford). 1999;38(8):779-788.
26. Beck A, Salem K, Krischak G, Kinzl L, Bischoff M, Schmelz A. Nonsteroidal anti-inflammatory drugs (NSAIDs) in the perioperative phase in traumatology and orthopedics effects on bone healing. Oper Orthop Traumatol. 2005;17(6):569-578.
27. Gajraj NM. The effect of cyclooxygenase-2 inhibitors on bone healing. Reg Anesth Pain Med. 2003;28(5):456-465.
28. Ebell MH. NSAIDs vs opiates for pain in acute renal colic. Am Fam Physician. 2004;70(9):1682.
29. Holdgate A, Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ. 2004;328(7453):1401.
30. Lundstam SO, Leissner KH, Wåhlander LA, Kral JG. Prostaglandin-synthetase inhibition with diclofenac sodium in treatment of renal colic: comparison with use of a narcotic analgesic. Lancet. 1982;1(8281):1096-1097.
31. Stacher G, Steinringer H, Schneider S, Mittelbach G, Winklehner S, Gaupmann G. Experimental pain induced by electrical and thermal stimulation of the skin in healthy man: sensitivity to 75 and 150 mg diclofenac sodium in comparison with 60 mg codeine and placebo. Br J Clin Pharmacol. 1986;21(1):35-43.
32. Kantor T, Cavaliere MB, Hopper M, Roepke S. A double-blind parallel comparison of ketoprofen, codeine, and placebo in patients with moderate to severe postpartum pain. J Clin Pharmacol. 1984;24(5-6):228-234.
33. O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain. 2000;85(1-2):209-215.
34. Pountos I, Georgouli T, Blokhuis TJ, Pape HC, Giannoudis PV. Pharmacological agents and impairment of fracture healing: what is the evidence? Injury. 2008;39(4):384-394.
35. Duellman TJ, Gaffigan C, Milbrandt JC, Allan DG. Multi-modal, pre-emptive analgesia decreases the length of hospital stay following total joint arthroplasty. Orthopedics. 2009;32(3):167.
36. Hebl JR, Dilger JA, Byer DE, et al. A pre-emptive multimodal pathway featuring peripheral nerve block improves perioperative outcomes after major orthopedic surgery. Reg Anesth Pain Med. 2008;33(6):510-517.
37. Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010;(6):CD007402.
38. Buchbinder R. Topical NSAIDs provide effective relief of acute musculoskeletal pain compared to placebo, with no increase in risk of adverse effects. Evid Based Med. 2010;15(6):177-178.
39. Abrams GJ, Solomon L, Meyers OL. A long-term study of diclophenac sodium in the treatment of rheumatoid arthritis and osteo-arthrosis. S Afr Med J. 1978;53(12):442-445.
40. Kirchheiner B, Trang L, Wollheim FA. Diclophenax sodium (Voltaren) in rheumatoid arthritis: a double-blind comparison with indomethacin and placebo. Int J Clin Pharmacol Biopharm. 1976;13(4):292-297.
41. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173-179.
42. Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(11):1-278, iii.
43. Poddubnyy D, Song IH, Sieper J. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2009;27(4 Suppl 55): S148-S151.
44. Maksymowych WP. Update on the treatment of ankylosing spondylitis. Ther Clin Risk Manag. 2007;3(6):1125-1133.
45. O'Brien JR. Effect of salicylates on human platelets. Lancet. 1968;1(7557):1431.
46. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA. 2004;292(24):3017-3023.
47. Richardson CM, Sharma RA, Cox G, O'Byrne KJ. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer. 2003;39(1):1-13.
48. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer. Semin Oncol. 2004;31(2 Suppl 7):45-52.
49. Bennett A, Del Tacca M. Proceedings: prostaglandins in human colonic carcinoma. Gut. 1975;16(5):409.
50. Kashfi K, Rigas B. Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans. 2005;33(Pt 4):724-727.
51. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol Disord Drug Targets. 2010;9(2):132-139.
52. Cotlier E. Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined with diabetes. Int Ophthalmol. 1981;3(3):173-177.
53. van Heyningen R, Harding JJ. A case-control study of cataract in Oxfordshire: some risk factors. Br J Ophthalmol. 1988;72(11): 804-808.
54. Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms. Rev Gastroenterol Disord. 2003;3 Suppl 4:S30-S39.
55. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989;11(2):158-162.
56. Holvoet J, Terriere L, van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study. Gut. 1991;32(7): 730-734.
57. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8900):769-772.
58. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996;156(14):1530-1536.
59. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241-249.
60. Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121(12):1092-1098.
61. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881-889.
62. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1984;310(9): 563-572.
63. Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000;151(5):488-496.
64. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490-496.
65. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009; 27(12):2332-2341.
66. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091.
67. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
68. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080.
69. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475-481.
70. Pountos I, Giannoudis PV, Jones E, et al. NSAIDs inhibit in vitro MSC chondrogenesis but not osteogenesis. J Cell Mol Med. Jan 11 2010. [Epub ahead of print].
71. Davis TR, Ackroyd CE. Non-steroidal anti-inflammator y agents in the management of Colles' fractures. Br J Clin Pract. 1988;42(5):184-189.
72. Adolphson P, Abbaszadegan H, Jonsson U, Dalen N, Sjoberg HE, Kalen S. No effects of piroxicam on osteopenia and recovery after Colles' fracture. A randomized, double-blind, placebo-controlled, prospective trial. Arch Orthop Trauma Surg. 1993;112(3):127-130.
73. Wurnig C, Schwameis E, Bitzan P, Kainberger F. Six-year results of a cementless stem with prophylaxis against heterotopic bone. Clin Orthop Relat Res. 1999;(361):150-158.
74. Giannoudis PV, MacDonald DA, Matthews SJ, Smith RM, Furlong AJ, de Boer P. Nonunion of the femoral diaphysis. The influence of reaming and non-steroidal anti-inflammatory drugs. J Bone Joint Surg Br. 2000;82(5):655-658.
75. Reuben SS, Ablett D, Kaye R. High dose nonsteroidal antiinflammatory drugs compromise spinal fusion. Can J Anaesth. 2005;52(5):506-512.
76. Reuben SS, Ekman EF. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am. 2005;87(3):536-542.
77. Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am Fam Physician. 2009;80(12):1371-1378.
78. Licata A, Calvaruso V, Cappello M, Craxì A, Almasio PL. Clinical course and outcomes of drug-induced liver injury: nimesulide as the first implicated medication. Dig Liver Dis. 2010;42(2):143-148.
79. Lapeyre-Mestre M, de Castro AM, Bareille MP, et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol. 2006;20(4):391-395.
80. Szczeklik A. Aspirin-induced asthma: a tribute to John Vane as a source of inspiration. Pharmacol Rep. 2010;62(3):526-529.
81. Sabry EY. The prevalence of aspirin-induced asthma in Saudian asthmatic patients. Allergol Immunopathol (Madr). 2010;38(4): 181-186.
82. Gosalakkal JA, Kamoji V. Reye syndrome and reye-like syndrome. Pediatr Neurol. 2008;39(3):198-200.
83. Fitzgerald DA. Aspirin and Reye syndrome. Paediatr Drugs. 2007;9(3):205-206.
84. Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195-204.
85. Damase-Michel C, Christaud J, Berrebi A, Lacroix I, Montastruc JL. What do pregnant women know about non-steroidal anti-inflammatory drugs? Pharmacoepidemiol Drug Saf. 2009;18(11):1034-1038.
86. Vroom F, van den Berg PB, de Jong-van den Berg LT. Prescribing of NSAIDs and ASA during pregnancy; do we need to be more careful? Br J Clin Pharmacol. 2008;65(2):275-276.
87. Bar-Oz B, Bulkowstein M, Benyamini L, et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf. 2003;26(13):925-935.
88. McEvoy GK. AHFS Drug Information. Bethesda (MD): American Society of Health-System Pharmacists; 2004:534-720.
89. British National Formulary. 52nd ed. London (UK): British Medical Association and Royal Pharmaceutical Society of Great Britain; 2005:513-522.